1. Introduction: Organs Without Donors
Kidney failure alone confines millions of people to dialysis, a therapy that sustains life but imposes a quality-of-life burden and a substantially reduced life expectancy compared with a functioning transplant. Human donor organs meet only a fraction of the need, and many patients die or deteriorate while waiting. Xenotransplantation — the transplantation of organs from another species into humans — proposes to close that gap by using pigs as a source of organs: pigs are of comparable organ size and physiology, breed rapidly, and, crucially, can now be genetically engineered with precision.
After decades in which hyperacute rejection made pig-to-human transplantation impossible, the period from 2022 to 2025 brought the first gene-edited pig hearts and kidneys into living patients, and in 2024-2025 the first formal clinical trials were authorised. This article explains the immunology that made xenotransplantation so difficult, the genetic edits designed to overcome it, the clinical milestones that have actually occurred, and the unresolved problems — particularly long-term rejection, graft durability, and infection risk — that keep the field experimental.
2. The Immunology of Xenograft Rejection
Human immunity attacks a pig organ through several distinct and sequential mechanisms, each of which had to be addressed.
- Hyperacute rejection. Humans and other primates carry pre-existing antibodies against carbohydrate antigens expressed on pig cells — above all galactose-α-1,3-galactose (α-Gal), absent in humans, together with the Sda blood-group antigen and N-glycolylneuraminic acid (Neu5Gc). These antibodies bind the graft endothelium and trigger complement-mediated destruction within minutes to hours. Eliminating α-Gal by knocking out the enzyme that produces it (GGTA1) was the single most important early advance.
- Complement and coagulation dysregulation. Even without antibody, porcine endothelial cells regulate human complement and blood clotting poorly, because porcine regulatory proteins do not efficiently control the human cascade. This causes thrombotic microangiopathy and consumptive coagulopathy — a major cause of graft loss in early non-human-primate experiments.
- Cellular and antibody-mediated rejection. T cells and later de-novo antibodies mediate slower rejection, which is managed with immunosuppression — typically costimulation blockade (for example, agents targeting the CD40/CD40L pathway) rather than, or in addition to, conventional regimens.
The genetic engineering strategy is therefore a checklist of edits that address specific, documented failure modes rather than a speculative rewiring of pig biology.
3. Genetic Engineering of the Donor Pig
Modern donor pigs carry a combination of knockouts and human transgenes, assembled with CRISPR-Cas9 within a single generation or clonally from an edited cell line. Three categories dominate:
- Removal of xenoantigens. Knockout of three carbohydrate antigens — α-Gal, Sda, and Neu5Gc (the «triple knockout») — removes the principal targets of pre-existing human antibodies. Removal of the porcine growth hormone receptor limits excessive graft growth.
- Human transgenes for regulation. Expression of human complement-regulatory proteins (such as CD46 and decay-accelerating factor) limits complement injury; expression of human thromboregulatory proteins (such as thrombomodulin and endothelial protein C receptor) addresses the coagulation mismatch; and anti-inflammatory genes (such as CD47 and heme oxygenase 1) further reduce injury.
- Inactivation of porcine endogenous retroviruses (PERVs). See Section 4.
The gene-edited pig heart transplanted in 2022 carried 10 edits; the 2025 clinical kidney product carried on the order of 69 edits, including the triple antigen knockout, multiple human transgenes, and PERV inactivation. The direction of travel is toward more edits, and toward standardised, well-characterised donor lines rather than bespoke animals.
4. PERVs and the Zoonosis Problem
Pigs carry porcine endogenous retroviruses — viral sequences integrated in the genome that cannot be removed by breeding or biosecure husbandry. Unlike conventional pathogens, PERVs are inherited, and there is a theoretical risk of cross-species transmission to a human recipient. Although in-vivo transmission to humans has not been documented, PERVs can infect human cells in vitro, so the risk was taken seriously.
Two landmark studies demonstrated that the risk is engineerable. In a porcine kidney cell line, CRISPR-Cas9 was used to disrupt all 62 copies of the PERV pol gene, reducing PERV transmission to human cells by more than a thousand-fold (Yang et al., 2015). Two years later, the same approach was applied to primary pig cells, and PERV-inactivated pigs were produced by somatic cell nuclear transfer (Niu et al., 2017). This is one of the clearest examples of a genome-wide editing problem solved by targeted CRISPR multiplexing. PERV inactivation does not address every zoonotic risk — donor animals are still raised in biosecure facilities and monitored for conventional pathogens — but it removes the most distinctive and feared hazard of the technology.
5. Clinical Milestones
5.1. The Decedent (Brain-Dead Recipient) Model
Before exposing living patients to risk, investigators used recipients maintained on life support whose families consented to research. In 2022, two such studies demonstrated that gene-edited pig kidneys produced urine and cleared creatinine and other solutes without hyperacute rejection, establishing feasibility of the pig-to-human kidney interface (Montgomery et al., 2022). The decedent model is now a recognised intermediate step for de-risking first-in-human xenotransplantation.
5.2. The First Pig Heart in a Living Patient (2022)
In January 2022, a 57-year-old man with end-stage heart failure who was ineligible for a conventional transplant received a heart from a pig with 10 gene edits, under a compassionate-use authorisation, with immunosuppression based on CD40 blockade. The graft functioned initially without apparent rejection, and the patient was weaned off extracorporeal support. However, on day 49 the graft suddenly failed with diastolic thickening, and life support was withdrawn on day 60. On autopsy the heart was oedematous, having nearly doubled in weight, with myocyte necrosis and red-cell extravasation but without evidence of typical rejection or microvascular thrombosis (Griffith et al., 2022). The mechanism was not fully established at the time of reporting, and the case illustrated that early function does not guarantee durable survival.
5.3. The First Pig Kidneys in Living Patients (2024-2025)
In March 2024, a 62-year-old man with end-stage kidney disease received a gene-edited pig kidney (the product carried 69 edits, including deletion of three glycan antigens, PERV inactivation, and seven human transgenes). The graft functioned immediately, creatinine fell from approximately 8 to 2 mg/dL within a week, and dialysis was no longer required. On day 8, an episode of T-cell-mediated rejection was detected and reversed with intensified immunosuppression. Despite sustained kidney function, the patient died suddenly of a cardiac event on day 52; autopsy showed severe coronary artery disease and ventricular scarring without evidence of xenograft rejection (Kawai et al., 2025). The case demonstrated that a pig kidney can maintain water and mineral balance in a manner broadly similar to a human kidney, and no pig-virus transmission was detected.
Later in 2024, a gene-edited pig kidney was transplanted into a living patient at NYU Langone under compassionate use. This recipient — a woman with long-standing kidney failure and very high levels of anti-human antibodies that made a conventional match unlikely — was discharged with normal kidney function and no need for dialysis, and became the longest-surviving recipient of a pig organ, with graft function extending for approximately 130 days before rejection required removal of the graft in April 2025. By late 2025, a further case was reported in which a recipient surpassed six months of survival with a functioning pig kidney, described in the scientific news literature as a landmark.
These outcomes should be read precisely. They establish that gene-edited pig organs can function in humans for weeks to months, that the early rejection events are detectable and, at least sometimes, reversible, and that no PERV transmission has been detected. They do not establish durability over years, and every one of these cases was performed under compassionate use rather than within a controlled trial.
6. The Transition to Regulated Trials
6.1. First Authorised Studies
In early 2025, the U.S. Food and Drug Administration cleared the first formal clinical trials of gene-edited pig kidneys. One programme was authorised to begin with a small number of patients (with provision to expand if early results are favourable), monitoring allograft longevity, rejection, and zoonosis; another began its pilot study in early 2025. These trials represent the field’s transition from compassionate-use case reports to prospective, protocol-driven evidence — the necessary condition for evaluating safety in a systematic, rather than anecdotal, way. The eligible patients remain those with limited options: individuals turned down for the human waitlist or at high risk of dying before a human organ becomes available.
6.2. Preclinical Foundations
The clinical cases were enabled by three decades of non-human-primate research, in which the combination of multi-gene editing and costimulation-blockade immunosuppression extended survival of pig kidney grafts in monkeys to the order of two years. That benchmark — years, not months — is the level of durability xenografts must achieve in humans to become a realistic alternative to dialysis.
7. Relevance to Lifespan and Healthspan
Xenotransplantation does not slow aging; it rescues its victims. A durable pig kidney could restore near-normal life expectancy to dialysis patients — a difference of years — and, at scale, unlimited organs would eliminate the waiting-list mortality that currently kills thousands each year. The longevity significance is therefore concentrated rather than general: entire categories of age-related death (renal failure, and potentially heart failure) would become treatable conditions rather than terminal ones. Realising that benefit depends on solving chronic rejection, on demonstrating graft durability over years, on preventing zoonosis, and on making the economics work in a way that does not simply create a new form of unequal access.
8. Risks and Ethical Dimensions
- Chronic and late rejection. The dominant unresolved problem is the durability of xenografts beyond months. Acute rejection episodes have been observed and treated; the behaviour of the grafts over years, and the immunosuppression required to sustain them, remain unknown.
- Physiological incompatibility. Porcine organs may not fully reproduce human function or regulatory feedback, particularly for endocrine and coagulation functions, over long periods.
- Zoonosis. Although PERVs have been largely addressed by inactivation and no transmission has been detected, the possibility of unknown porcine pathogens, and the need for lifelong recipient surveillance, remain open concerns. Donor animals are raised in biosecure facilities and screened.
- Immunosuppression burden. The regimens used in the clinical cases are intensive, and their long-term infection and toxicity risks must be weighed against dialysis.
- Animal welfare and ethics. The use of pigs as organ sources raises questions about animal welfare and about the ethics of creating genetically modified animals for human benefit.
- Equity and allocation. If engineered organs become available, decisions about who receives them, and at what cost, will require explicit ethical and policy frameworks rather than market allocation alone.
Regulatory agencies now maintain dedicated xenotransplantation frameworks addressing source-animal qualification, infection surveillance, and long-term recipient follow-up — evidence that the field has moved from prohibition to managed clinical development.
9. Prospects
Durability is the decisive endpoint. The question that will determine whether xenotransplantation becomes routine is not whether a pig kidney can function for weeks, but whether it can function for years without prohibitive immunosuppression. The authorised trials are designed to answer this.
Kidney first. Because dialysis provides a fallback and kidney function is easier to monitor than cardiac or pulmonary function, the kidney is the most tractable organ and the first to enter trials. Heart, lung, and liver xenotransplantation will follow a slower path.
Standardised donor lines. Reliable supply depends on well-characterised, genetically defined donor pigs, with consistent edit sets and rigorous health monitoring, rather than case-by-case animals.
Convergence with engineered alternatives. Xenotransplantation competes and may eventually combine with bioprinted and engineered organs; in the interim, it bridges the gap for patients with organ failure today. The two technologies share the same ultimate goal — eliminating the donor shortage — and the same requirements for durable function and immune compatibility.
10. Conclusion
Xenotransplantation has crossed the threshold from impossible to investigational. Genetic engineering has removed the hyperacute-rejection barrier that defeated earlier attempts, PERV risk has been substantially engineered down, and gene-edited pig kidneys and hearts have functioned in living patients for weeks to months. The first regulated clinical trials are now the appropriate context for evaluation.
What remains is durability and control: extending graft survival from months to years, managing chronic rejection and immunosuppression, and ensuring long-term infection surveillance. If current survival curves extend and the trials demonstrate safety and durable function, engineered pig organs could become the most consequential near-term life-extension technology for patients with organ failure — a bridge between today’s dialysis wards and the still-distant goal of purpose-built replacement organs.
Sources and Key Research Centers
- Griffith BP et al. «Genetically modified porcine-to-human cardiac xenotransplantation.» New England Journal of Medicine, 2022; 387(1): 35-44. DOI: 10.1056/NEJMoa2201422 — First gene-edited pig heart in a living patient; 10 edits; graft failure on day 49, death on day 60.
- Montgomery RA et al. «Results of two cases of pig-to-human kidney xenotransplantation.» New England Journal of Medicine, 2022; 386(20): 1889-1898. DOI: 10.1056/NEJMoa2120238 — Decedent-model pig-to-human kidney transplants demonstrating function without hyperacute rejection.
- Kawai T et al. «Xenotransplantation of a porcine kidney for end-stage kidney disease.» New England Journal of Medicine, 2025; 392(19): 1933-1940. DOI: 10.1056/NEJMoa2412747 — First gene-edited pig kidney in a living patient; 69 edits; immediate function, T-cell-mediated rejection reversed, cardiac death on day 52.
- Yang L et al. «Genome-wide inactivation of porcine endogenous retroviruses (PERVs).» Science, 2015; 350(6264): 1101-1104. DOI: 10.1126/science.aad1191 — CRISPR-Cas9 disruption of all 62 PERV copies in a pig cell line.
- Niu D et al. «Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9.» Science, 2017; 357(6357): 1303-1307. DOI: 10.1126/science.aan4187 — Generation of PERV-inactivated pigs via somatic cell nuclear transfer.
- FDA: Cellular and Gene Therapy Products / Xenotransplantation — Regulatory framework for xenotransplantation, including source-animal qualification and long-term surveillance.
- ClinicalTrials.gov — Active xenotransplantation trials and expanded-access protocols.